Zacks Research Has Positive Outlook for ResMed Q2 Earnings

ResMed Inc. (NYSE:RMD) – Zacks Research lifted their Q2 2026 earnings estimates for ResMed in a research report issued on Tuesday, November 18th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings of $2.62 per share for the quarter, up from their previous forecast of $2.61. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q3 2026 earnings at $2.65 EPS, Q4 2026 earnings at $2.67 EPS, FY2026 earnings at $10.49 EPS, Q1 2027 earnings at $2.61 EPS, Q2 2027 earnings at $2.71 EPS, FY2027 earnings at $11.12 EPS, Q1 2028 earnings at $3.09 EPS and FY2028 earnings at $12.70 EPS.

ResMed (NYSE:RMD) last posted its earnings results on Friday, October 31st. The medical equipment provider reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. ResMed had a net margin of 27.22% and a return on equity of 25.62%. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the previous year, the business posted $2.20 EPS. The business’s quarterly revenue was up 9.1% on a year-over-year basis.

Several other equities analysts have also commented on RMD. Piper Sandler boosted their price target on ResMed from $248.00 to $270.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Weiss Ratings downgraded shares of ResMed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. UBS Group raised shares of ResMed to a “strong-buy” rating in a research note on Tuesday, September 16th. KeyCorp boosted their price objective on shares of ResMed from $298.00 to $299.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Finally, William Blair upgraded ResMed to a “strong-buy” rating in a research note on Friday, August 1st. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $297.45.

ResMed Trading Up 0.7%

Shares of RMD opened at $246.38 on Wednesday. ResMed has a 12 month low of $199.92 and a 12 month high of $293.81. The stock’s 50-day moving average is $264.92 and its two-hundred day moving average is $263.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.44 and a quick ratio of 2.53. The stock has a market cap of $35.96 billion, a PE ratio of 25.91, a P/E/G ratio of 1.75 and a beta of 0.87.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, November 13th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Thursday, November 13th. ResMed’s dividend payout ratio (DPR) is 24.56%.

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $252.05, for a total value of $504,100.00. Following the completion of the sale, the director directly owned 66,110 shares in the company, valued at approximately $16,663,025.50. The trade was a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Witte Jan De sold 487 shares of ResMed stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $250.25, for a total transaction of $121,871.75. Following the completion of the transaction, the director directly owned 5,319 shares of the company’s stock, valued at approximately $1,331,079.75. This represents a 8.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 18,607 shares of company stock valued at $4,919,501 in the last three months. Corporate insiders own 0.65% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of ResMed by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider’s stock worth $5,211,940,000 after purchasing an additional 293,515 shares during the period. State Street Corp increased its position in ResMed by 1.0% in the second quarter. State Street Corp now owns 6,615,852 shares of the medical equipment provider’s stock worth $1,706,890,000 after buying an additional 64,448 shares during the period. Geode Capital Management LLC lifted its stake in ResMed by 2.4% in the second quarter. Geode Capital Management LLC now owns 4,215,145 shares of the medical equipment provider’s stock valued at $1,083,409,000 after buying an additional 98,717 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of ResMed by 2.5% during the first quarter. Northern Trust Corp now owns 1,744,541 shares of the medical equipment provider’s stock valued at $390,516,000 after acquiring an additional 41,951 shares during the period. Finally, Norges Bank bought a new position in shares of ResMed during the second quarter worth about $306,452,000. 54.98% of the stock is owned by institutional investors and hedge funds.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.